Guidelines to document H. pylori antimicrobial resistance in the North America: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{CMG}}; {{AE}} {{MKK}}, {{SSW}} | {{CMG}}; {{AE}} {{MKK}}, {{SSW}} | ||
==2017 ACG Guidelines to document H. pylori antimicrobial resistance in the North America | ==2017 ACG Guidelines to document H. pylori antimicrobial resistance in the North America== | ||
{| class="wikitable" | {| class="wikitable" | ||
|- | |- | ||
| Line 11: | Line 11: | ||
|- | |- | ||
| bgcolor="LightGreen" |2.Concomitant therapy consisting of a PPI, clarithromycin, amoxicillin and a nitroimidazole for 10–14 days is a recommended | | bgcolor="LightGreen" |2.Concomitant therapy consisting of a PPI, clarithromycin, amoxicillin and a nitroimidazole for 10–14 days is a recommended first-line treatment option | ||
|- | |- | ||
|} | |} | ||
Revision as of 19:38, 1 December 2017
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Manpreet Kaur, MD [2], Sargun Singh Walia M.B.B.S.[3]
2017 ACG Guidelines to document H. pylori antimicrobial resistance in the North America
| Strong recommendation |
| 1.Bismuth quadruple therapy consisting of a PPI, bismuth, tetracycline, and a nitroimidazole for 10–14 days is a recommended fi rst-line treatment option.
Bismuth quadruple therapy is particularly attractive in patients with any previous macrolide exposure or who are allergic to penicillin |
| 2.Concomitant therapy consisting of a PPI, clarithromycin, amoxicillin and a nitroimidazole for 10–14 days is a recommended first-line treatment option |